Dosimetry Data Infrastructure for Individualized Radiopharmaceutical Therapy: International Experience and a Proposed Framework for China

Background/Objectives: There is increasing interest in moving selected radiopharmaceutical therapy (RPT) applications toward treatment informed by patient-specific quantitative data. Patient-specific dosimetry supports this transition, but routine implementation remains limited by methodological heterogeneity and incomplete linkage of absorbed dose with response, toxicity, and subsequent treatment decisions. This review examines evidence relevant to longitudinal dosimetry infrastructure and proposes a framework for China.

Methods

This narrative review mapped evidence from established therapies, including 177Lu-DOTATATE, 177Lu-PSMA-617, 131I-NaI, and 131I-meta-iodobenzylguanidine (131I-MIBG), with 90Y microsphere selective internal radiation therapy used as a methodologically distinct comparator. International registries, quantitative imaging standards, and dosimetry resources were reviewed in parallel.